Immutep Touts Encouraging Data From Efti Triple Combination Therapy In Lung Cancer Setting

  • Immutep Limited IMMP announced new data in 1st line non-small cell lung cancer from the INSIGHT-003 Phase I trial evaluating eftilagimod alpha in conjunction with standard-of-care anti-PD-1 therapy and doublet chemotherapy (carboplatin/pemetrexed).
  • The triple combination therapy remains well-tolerated and continues to show favorable initial efficacy signals, attaining a 67% overall response rate (ORR) and 91% disease control rate (DCR) in advanced or metastatic non-squamous 1st line non-small cell lung cancer patients (N=21). 
  • Related: Immutep Shares Spike As Cancer Treatment Shows Favorable Results In Phase 2 Trial.
  • The 67% ORR regardless of PD-L1 expression, and 65% response rate in patients with PD-L1 TPS <50% for the triple combination compare favorably to reported results from a registrational trial of anti-PD-1 and doublet chemotherapy in the same patient population that yielded an ORR of 48% regardless of PD-L1 expression and a response rate of 40.8% in patients with PD-L1 TPS <50%.
  • The INSIGHT-003 trial was recently expanded to enroll 50 patients based on the favorable safety and efficacy results, and additional data is expected to be presented at a major medical conference in H2 CY2023.
  • Price Action: IMMP shares are up 10.8% at $2.5489 on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechEquitiesNewsPenny StocksHealth CareMarketsMoversGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!